MorphoSys

Apr 29, 2019

I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma

Nov 15, 2018

MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210

Nov 07, 2018

Sosei Enters Collaboration to Combine Pioneering DNA Technologies With StaR® Technology to Accelerate New Drug Discovery

Aug 07, 2018

I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

Jun 04, 2018

Sosei Announces Appointment of Chris Cargill as Interim CFO

May 07, 2018

Xencor Reports First Quarter 2018 Financial Results

Feb 13, 2018

Global IP Exchange UK Releases Global IP UK Pre-Event Report 2018

Dec 01, 2017

I-Mab Biopharma Partners with MorphoSys on Cancer Investigational Medicine

Oct 02, 2017

Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors

Aug 07, 2017

Xencor Reports Second Quarter 2017 Financial Results